All News

RheumNow Podcast square

Trends and Innovations from Barcelona (6.20.2025)

Jack Cush, MD

Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

Read Article
heart in a puzzle

What would it take for JAKs to ROCK the boat?

David Liew, FRACP

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.

Read Article
eular

EULAR 2025 – Day 4 Report

Jack Cush, MD

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY
Dr. John Cush RheumNow ( View Tweet)
JAK Safety Update Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroids, Not JAKi, Are the Real Infection Risk Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain. https://t.co/rLpyo1UNjd https://t.co/bDfdLTEM1N

Links:

Dr. John Cush RheumNow ( View Tweet)
Seronegative Arthritis Breakthroughs Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb
Dr. John Cush RheumNow ( View Tweet)
RA Care Should be Guided by Need—Not Age Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis," at EULAR 2025 in Barcelona, Spain. https://t.co/zKHXZSVLJy https://t.co/w6CkRy2yIA

Links:

Dr. John Cush RheumNow ( View Tweet)
POETYK PsA-1 Deucravacitinib TYK2i RCT Ph 3 ACR 20 DEU 54% vs. 34% PBO wk 16 ACR 50 DEU 23% vs. 14% PBO also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA Less Rx progression @RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA. Also improved QoL, skin, and MSK outcomes. Post hoc: slowed radiographic progression. Well tolerated & no new safety signals @RheumNow #EULAR2025 #LB0001

Mrinalini Dey DrMiniDey ( View Tweet)

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

#infections in #JAKi @drdavidliew #JAKi sl ⬆️ infection risk vs #TNFi ⬆️HZ w JAKi JAKi same risk w #latent #TB #LTBI and new TB ⬇️in JAKi v bDMARDs He didn’t discuss TYK2i Reassuring - risk⬇️ over time for infection @RheumNow #EULAR2025 @eular_org JAKi & infection https://t.co/KVsY2gXVkQ

Links:

Janet Pope Janetbirdope ( View Tweet)
Management of HLH/MAS and modes of action of advanced therapies Jessica Manson @RheumNow #EULAR2025 https://t.co/Op3u53ZXeK

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
JAKi: expanding RMD indications—but important safety concerns to consider ⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF ⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi 🗣️ Patients rank infection risk as top concern @rheumnow #EULAR2025 https://t.co/RJRDWQjqNC

Links:

Jiha Lee JihaRheum ( View Tweet)
Age & dose ⬆️ infections in JAKi Not all JAKi are created w equal risk ⁦@RheumNow⁩ ⁦@eular_org⁩ #EULAR2015 ⁦@drdavidliew⁩ #JAKi & #infection https://t.co/F7zLUBuzJR

Links:

Janet Pope Janetbirdope ( View Tweet)
#Cancer is not ⬆️in JAKi vs #bDMARDs in #rheumatoid #arthritis When adjusted for #confounders #JAKPOT data Now you see it (unadjusted ⬆️risk) Now you don’t (adjusted =#malignancy) JAKi vs bDMARDs in RA EULAR2025 @RheumNow @eular_org #JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×